Cardiac microcurrent (C-MIC) therapy is being investigated for heart failure (HF). Early studies, including the C-MIC II trial, showed potential benefits with a subcutaneous implant compared to controls. Analysis of CPET data revealed improvements in absolute peak VO2, peak metabolic equivalents, and percent-predicted peak VO2 in patients receiving C-MIC. A post hoc analysis of the C-MIC II trial, utilizing blinded core lab CPET results, confirmed these findings. The C-MIC II trial, involving 65 randomized patients, demonstrated improvements in left ventricular ejection fraction (LVEF), symptoms, functional capacity, and quality of life. A subsequent subcutaneous C-MIC approach, termed C-MIC III, showed comparable improvements in LVEF, 6-minute walking distance, and quality of life scores when compared to a surgical implant group. Initial results from C-MIC III involved 10 patients. Future research, C-MIC IV, will include a sham-controlled crossover trial with 60 patients and will investigate potential interference from existing implants, such as implantable cardioverter-defibrillators. Concerns remain regarding infection rates associated with the subcutaneous device, with one infection reported in the C-MIC III study.